The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Activity of Thalidomide in AIDS-Related Kaposi’s Sarcoma
Abstract
PURPOSE: To assess the toxicity and activity of oral thalidomide in Kaposi’s sarcoma (KS) in a phase II dose-escalation study. PATIENTS AND METHODS: Human immunodeficiency virus (HIV)–seropositive patients with biopsy-confirmed KS that progressed over the 2 months before enrollment received an initial dose of 200 mg/d of oral thalidomide in a phase II study. The dose was increased to a maximum of 1,000 mg/d for up to 1 year. Anti-HIV therapy was maintained during the study period. Toxicity, tumor response, immunologic and angiogenic factors, and virologic parameters were assessed. RESULTS: Twenty patients aged 29 to 49 years with a median CD4 count of 246 cells/mm 3(range, 14 to 646 cells/mm 3) were enrolled. All patients were assessable for toxicity, and 17 for response. Drowsiness in nine and depression in seven patients were the most frequent toxicities observed. Eight (47%; 95% confidence interval [CI], 23% to 72%) of the 17 assessable patients achieved a partial response, and an additional two patients had stable disease. Based on all 20 patients treated, the response rate was 40% (95% CI, 19% to 64%). The median thalidomide dose at the time of response was 500 mg/d (range, 400 to 1,000 mg/d). The median duration of drug treatment was 6.3 months, and the median time to progression was 7.3 months. CONCLUSION: Oral thalidomide was tolerated in this population at doses up to 1,000 mg/d for as long as 12 months and was found to induce clinically meaningful anti-KS responses in a sizable subset of the patients. Additional studies of this agent in KS are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's Sarcoma
Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M., & Moore, P. S. (1994) · Science · doi:10.1126/science.7997879 · Cited by 5,654
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Cesarman, E., Chang, Y., Moore, P. S., Said, J. W., & Knowles, D. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505043321802 · Cited by 2,818
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Definition of Two Angiogenic Pathways by Distinct α v Integrins
Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., & Cheresh, D. A. (1995) · Science · doi:10.1126/science.270.5241.1500 · Cited by 1,321
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.699 · Cited by 1,192
Moore, P. S., & Chang, Y. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505043321801 · Cited by 1,078
Molecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV
Moore, P. S., Boshoff, C., Weiss, R. A., & Chang, Y. (1996) · Science · doi:10.1126/science.274.5293.1739 · Cited by 904
Ensoli, B., Barillari, G., Salahuddin, S. Z., Gallo, R. C., & Wong-Staal, F. (1990) · Nature · doi:10.1038/345084a0 · Cited by 896
Bais, C., Santomasso, B., Coso, O., Arvanitakis, L., Raaka, E. G., Gutkind, J. S., Asch, A. S., Cesarman, E., Gerhengorn, M. C., & Mesri, E. A. (1998) · Nature · doi:10.1038/34193 · Cited by 829
Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells
Boshoff, C., Schulz, T. F., Kennedy, M. M., Graham, A. K., Fisher, C., Thomas, A., McGee, J. O., Weiss, R. A., & O'Leary, J. J. (1995) · Nature Medicine · doi:10.1038/nm1295-1274 · Cited by 681
Ensoli, B., Gendelman, R., Markham, P., Fiorelli, V., Colombini, S., Raffeld, M., Cafaro, A., Chang, H.-K., Brady, J. N., & Gallo, R. C. (1994) · Nature · doi:10.1038/371674a0 · Cited by 570
Krown, S. E., Metroka, C., & Wernz, J. C. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1201 · Cited by 478
AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6.
Miles, S. A., Rezai, A. R., Salazar-González, J. F., Vander Meyden, M., Stevens, R. H., Logan, D. M., Mitsuyasu, R. T., Taga, T., Hirano, T., & Kishimoto, T. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4068 · Cited by 475
Angiogenic and HIV-Inhibitory Functions of KSHV-Encoded Chemokines
Boshoff, C., Endo, Y., Collins, P. D., Takeuchi, Y., Reeves, J. D., Schweickart, V. L., Siani, M. A., Sasaki, T., Williams, T. J., Gray, P. W., et al. (1997) · Science · doi:10.1126/science.278.5336.290 · Cited by 469
AIDS-Kaposi's Sarcoma-Derived Cells Express Cytokines with Autocrine and Paracrine Growth Effects
Ensoli, B., Nakamura, S., Salahuddin, S. Z., Biberfeld, P., Larsson, L., Beaver, B., Wong-Staal, F., & Gallo, R. C. (1989) · Science · doi:10.1126/science.2643161 · Cited by 460
Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., von Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2353 · Cited by 438
Jacobson, J. M., Greenspan, J. S., Spritzler, J., Ketter, N., Fahey, J. L., Jackson, J. B., Fox, L., Chernoff, M., Wu, A. W., MacPhail, L. A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705223362103 · Cited by 420
Nicholas, J., Ruvolo, V. R., Burns, W. H., Sandford, G., Wan, X., Ciufo, D., Hendrickson, S. B., Guo, H.-G., Hayward, G. S., & Reixz, M. S. (1997) · Nature Medicine · doi:10.1038/nm0397-287 · Cited by 389
Krown, S. E., Testa, M. A., & Huang, J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.9.3085 · Cited by 303
Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent
Bauer, K. S., Dixon, S. C., & Figg, W. D. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00046-x · Cited by 295
Self-citationMchugh, S. M., Rifkin, I. R., Deighton, J., Wilson, A. B., Lachmann, P. J., Lockwood, C. M., & Ewan, P. W. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb05527.x · Cited by 263
The Natural History of Kaposi's Sarcoma in the Acquired Immunodeficiency Syndrome
SAFAI, B., JOHNSON, K. G., MYSKOWSKI, P. L., KOZINER, B., YANG, S. Y., CUNNINGHAM-RUNDLES, S., GODBOLD, J. H., & DUPONT, B. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-5-744 · Cited by 247
Thalidomide inhibits the replication of human immunodeficiency virus type 1.
Makonkawkeyoon, S., Limson-Pobre, R. N., Moreira, A. L., Schauf, V, & Kaplan, G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.5974 · Cited by 231
Treatment of HIV-associated Kaposi's sarcoma with paclitaxel
Saville, M. W., Lietzau, J., Pluda, J. M., Wilson, W. H., Humphrey, R. W., Feigel, E., Steinberg, S. M., Broder, S., Yarchoan, R., Odom, J., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92654-2 · Cited by 208
Self-citationSamaniego, F., Markham, P. D., Gendelman, R., Watanabe, Y., Kao, V., Kowalski, K., SONNABEND, J. A., Pintus, A., Gallo, R. C., & Ensoli, B. (1998) · PubMed · Cited by 184
Welles, L., Saville, M. W., Lietzau, J., Pluda, J. M., Wyvill, K. M., Feuerstein, I., Figg, W. D., Lush, R., Odom, J., Wilson, W. H., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1112 · Cited by 174
Self-citationNorthfelt, D. W., Dezube, B. J., Thommes, J. A., Levine, R., Von Roenn, J. H., Dosik, G. M., Rios, A., Krown, S. E., DuMond, C., & Mamelok, R. D. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.653 · Cited by 170
Dezube, B. J., Roenn, J. H. V., Holden‐Wiltse, J., Cheung, T., Remick, S. C., Cooley, T. P., Moore, J., Sommadossi, J., Shriver, S., Suckow, C., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1444 · Cited by 129
Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre
Fife, K., Phillips, R. H., Howard, M. R., et al. (1998) · International Journal of STD & AIDS · doi:10.1258/0956462981921512 · Cited by 125
Pharmacokinetics of thalidomide in an elderly prostate cancer population
Figg, W. D., Raje, S. V., Bauer, K. S., Tompkins, A. C., Venzon, D. J., Bergan, R. C., Chen, A. P., Hamilton, M., Pluda, J. M., & Reed, E. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js980172i · Cited by 120
Self-citationSamaniego, F., Markham, P. D., Gendelman, R., Gallo, R. C., & Ensoli, B. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.4.1887 · Cited by 118
Honda, M., KITAMURA, K., Mizutani, Y., Oishi, M., Arai, M., Okura, T., Igarahi, K., Yasukawa, K., Hirano, T., Kishimoto, T., et al. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.12.4059 · Cited by 102
Confidence Limits for Probability of Response in Multistage Phase II Clinical Trials
Atkinson, E. N., & Brown, B. W. (1985) · Biometrics · doi:10.2307/2531294 · Cited by 101
Thalidomide Stimulates T Cell Responses and Interleukin 12 Production in HIV-Infected Patients
Haslett, P. A. J., Klausner, J. D., Makonkawkeyoon, S., Moreira, A. L., Metatratip, P., Boyle, B., Kunachiwa, W., Maneekarn, N., Vongchan, P., Corral, L. G., et al. (1999) · AIDS Research and Human Retroviruses · doi:10.1089/088922299310269 · Cited by 83
Thalidomide and Thalidomide Analogs Reduce HIV Type 1 Replication in Human Macrophages in Vitro
Moreira, A. L., Corral, L. G., Ye, W., JOHNSON, B., STIRLING, D., Muller, G. W., Freedman, V. H., & Kaplan, G. (1997) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1997.13.857 · Cited by 76
Regression of AIDS-Related Kaposi's Sarcoma During Therapy with Thalidomide
Soler, R. A., Howard, M. R., Brink, N. S., Gibb, D. M., Tedder, R. S., & Nadal, D. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.3.501 · Cited by 74
Bailey, J., Pluda, J. M., Foli, A., Saville, M. W., Bauza, S., Adamson, P. C., Murphy, R. F., Cohen, R., Broder, S., & Yarchoan, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1966 · Cited by 47
Self-citationPearson, J. M. H., & VEDAGIRI, M. (1969) · Leprosy Review · doi:10.5935/0305-7518.19690022 · Cited by 44
Increased bFGF level in the serum of patients with phenytoin-induced gingival overgrowth.
Sasaki, T., & Maita, E. (1998) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.1998.tb02362.x · Cited by 32
Phase II Study of Pentosan Polysulfate (PPS) in Patients with AIDS-related Kaposi's Sarcoma
Schwartsmann, G., Sprinz, E., Kalakun, L., et al. (1996) · Tumori Journal · doi:10.1177/030089169608200412 · Cited by 31
Jones, P. D., Shelley, L., & Wakefield, D. (1992) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-199212000-00010 · Cited by 11
Cited by
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Franks, M. E., Macpherson, G. R., & Figg, W. D. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16308-3 · Cited by 615
Self-citationNF-κB as a therapeutic target in cancer
Orlowski, R. Z., & Baldwin, A. S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02375-4 · Cited by 553
Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer
Dahut, W. L., Gulley, J. L., Arlen, P. M., Liu, Y., Fedenko, K. M., Steinberg, S. M., Wright, J. J., Parnes, H., Chen, C. C., Jones, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.074 · Cited by 351
Self-citationHengge, U. R., Ruzicka, T., Tyring, S. K., Stuschke, M., Roggendorf, M., Schwartz, R. A., & Seeber, S. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00263-3 · Cited by 329
Metadata
- Authors
- Little, R. F., Wyvill, K. M., Pluda, J. M., Welles, L., Marshall, V., Figg, W. D., Newcomb, F. M., Tosato, G., Feigal, E., Steinberg, S. M., Whitby, D., Goedert, J. J., & Yarchoan, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-07-01
- Volume
- 18
- Issue
- 13
- Pages
- 2593-2602
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1946820747
- Cited by
- 290
- References
- 43
- FWCI
- 11.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.